United States securities and exchange commission logo

                     April 5, 2021

       Luca Santarelli
       Chief Executive Officer
       VectivBio Holding AG
       Aeschevorstadt 36
       4051 Basel

                                                        Re: VectivBio Holding
                                                            Amendment No. 1 to
Registration Statement on Form F-1
                                                            Filed April 5, 2021
                                                            File No. 333-254523

       Dear Dr. Santarelli:

             We have reviewed your amended registration statement and have the
       comments. In some of our comments, we may ask you to provide us with
information so we
       may better understand your disclosure.

              Please respond to this letter by amending your registration
statement and providing the
       requested information. If you do not believe our comments apply to your
facts and
       circumstances or do not believe an amendment is appropriate, please tell
us why in your

              After reviewing any amendment to your registration statement and
the information you
       provide in response to these comments, we may have additional comments.
Unless we note
       otherwise, our references to prior comments are to comments in our March
31, 2021 letter.
 Luca Santarelli
FirstName   LastNameLuca
VectivBio Holding   AG Santarelli
April       NameVectivBio Holding AG
       5, 2021
April 25, 2021 Page 2
FirstName LastName
Amendment No. 1 to Registration Statement on Form F-1, Filed April 5, 2021

Overview, page 91

1.       We note the footnote to your pipeline table currently says you plan to
"initiate the safety
         and efficacy of apraglutide" in additional indications in Pediatric
SBS-IF and Acute Graft
         Versus Host Disease. We also note that your table appears to indicate
that you have
         completed Phase 2 trials for Pediatric SBS-IF and Phase 1 trials for
Acute Graft Versus
         Host Disease. To the extent you are relying on data from the Adult
SBS-IF trials, please
         clarify. Alternatively, explain why the graph appears to indicate some
Pediatric SBS-IF
         and Acute Graft Versus Host trials have been completed and your
footnote indicates plans
         to initiate trials in these areas.
       You may contact Jeanne Baker at 202-551-3691 or Terence O'Brien at
202-551-3355 if
you have questions regarding comments on the financial statements and related
matters. Please
contact Margaret Schwartz at 202-551-7153 or Suzanne Hayes at 202-551-3675 with
any other


                                                              Division of
Corporation Finance
                                                              Office of Life
cc:      Ryan Sansom, Esq.